{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:03:33Z","timestamp":1756425813139,"version":"3.44.0"},"reference-count":25,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,3,1]]},"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>Hepatic veno-occlusive disease (VOD)\/sinusoidal obstructive syndrome (SOS) is a severe complication that can occur following haematopoietic stem cell transplant (HSCT) with high-intensity conditioning chemotherapy regimens. Severe VOD\/SOS, often characterised by multiorgan failure, is associated with a high mortality rate. This case report details the complex clinical course of a male patient in his mid-20s, recently diagnosed with B cell acute lymphoblastic leukaemia, who underwent allogeneic HSCT. Based on the 2023 European Society for Blood and Marrow Transplantation (EBMT) criteria, the patient developed very severe VOD\/SOS, prompting immediate treatment with defibrotide. Unexpectedly, he developed profound hyperammonaemia exceeding 900\u2009\u00b5mol\/L, leading to encephalopathy and cerebral oedema. Despite aggressive interventions including defibrotide, lactulose, rifampin and haemodialysis, the patient passed away due to cerebral oedema and pulseless electrical activity arrest. We theorise the hyperammonaemia is disproportionate to his hepatic dysfunction and is possibly secondary to an acquired defect of the urea synthesis consistent with idiopathic hyperammonaemia, a rare complication in patients receiving intense conditioning chemotherapy.<\/jats:p>","DOI":"10.1136\/bcr-2023-258876","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T13:00:52Z","timestamp":1711026052000},"page":"e258876","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Hepatic veno-occlusive disease complicated with extreme hyperammonaemia (920 \u00b5mol\/L) treated with defibrotide, lactulose, rifampin and haemodialysis"],"prefix":"10.1136","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0895-1869","authenticated-orcid":false,"given":"Maciej","family":"Kabat","sequence":"first","affiliation":[{"name":"Internal Medicine, Hackensack Meridian Hackensack University Medical Center, Hackensack, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarvarinder","family":"Gill","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Hackensack Meridian Hackensack University Medical Center, Hackensack, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Kim","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine, Hackensack Meridian Hackensack University Medical Center, Hackensack, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karan","family":"Omidvari","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine, Hackensack Meridian Hackensack University Medical Center, Hackensack, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Lee","sequence":"additional","affiliation":[{"name":"Pulmonary and Critical Care Medicine, Hackensack Meridian Hackensack University Medical Center, Hackensack, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,3,21]]},"reference":[{"key":"2025082801372014000_17.3.e258876.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.02.018"},{"key":"2025082801372014000_17.3.e258876.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.08.024"},{"key":"2025082801372014000_17.3.e258876.3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41409-023-01992-8","article-title":"Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT)","volume":"58","author":"Mohty","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"2025082801372014000_17.3.e258876.4","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.bbmt.2017.07.021","article-title":"Consensus report by pediatric acute lung injury and sepsis investigators and pediatric blood and marrow transplantation consortium joint working committees: supportive care guidelines for management of veno-occlusive disease in children and adolescents, part 1: focus on investigations, prophylaxis, and specific treatment","volume":"23","author":"Bajwa","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025082801372014000_17.3.e258876.5","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.65"},{"key":"2025082801372014000_17.3.e258876.6","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-43806-3","article-title":"Hokus-10 scoring system predicts the treatment outcome for sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Shiratori","year":"2023","journal-title":"Sci Rep"},{"key":"2025082801372014000_17.3.e258876.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.05.025"},{"key":"2025082801372014000_17.3.e258876.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.09.024"},{"key":"2025082801372014000_17.3.e258876.9","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/bmt.2014.16","article-title":"MTHFR C677T\/A1298C genotype: a possible risk factor for liver sinusoidal obstruction syndrome","volume":"49","author":"Efrati","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"2025082801372014000_17.3.e258876.10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017008375"},{"key":"2025082801372014000_17.3.e258876.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-676924"},{"key":"2025082801372014000_17.3.e258876.12","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/bjh.15267","article-title":"Final results from a Defibrotide treatment-IND study for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome","volume":"181","author":"Kernan","year":"2018","journal-title":"Br J Haematol"},{"key":"2025082801372014000_17.3.e258876.13","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-111396","article-title":"Cost-effectiveness of Defibrotide for the treatment of veno-occlusive disease\/sinusoidal obstruction syndrome (VOD\/SOS) with multi-organ dysfunction (MOD) post-hematopoietic stem cell transplantation (HSCT) in Canada","volume":"132","author":"Belsey","year":"2018","journal-title":"Blood"},{"key":"2025082801372014000_17.3.e258876.14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1080\/13696998.2021.1916749","article-title":"Cost-effectiveness analysis of Defibrotide in the treatment of patients with severe veno-occlusive disease\/sinusoidal obstructive syndrome with Multiorgan dysfunction following hematopoietic cell transplantation in Spain","volume":"24","author":"Carcedo Rodriguez","year":"2021","journal-title":"J Med Econ"},{"key":"2025082801372014000_17.3.e258876.15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/13696998.2016.1275652","article-title":"The budget impact and cost-effectiveness of Defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplant","volume":"20","author":"Veenstra","year":"2017","journal-title":"J Med Econ"},{"key":"2025082801372014000_17.3.e258876.16","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0002-9343(88)80239-0","article-title":"Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases","volume":"85","author":"Mitchell","year":"1988","journal-title":"Am J Med"},{"key":"2025082801372014000_17.3.e258876.17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00280-022-04476-6","article-title":"Idiopathic Hyperammonemic encephalopathy secondary to Gemcitabine\u2013cisplatin treatment","volume":"90","author":"Verkerk","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025082801372014000_17.3.e258876.18","doi-asserted-by":"crossref","first-page":"199","DOI":"10.5144\/1658-3876.2010.199","article-title":"Idiopathic hyperammonemia after chemotherapy with Vinorelbine, Topotecan, and cisplatin in a patient with acute lymphocytic leukemia","volume":"3","author":"Chen","year":"2010","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"2025082801372014000_17.3.e258876.19","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bmt.1705346","article-title":"Idiopathic hyperammonemia following high-dose chemotherapy","volume":"37","author":"Espin\u00f3s","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"2025082801372014000_17.3.e258876.20","first-page":"1119","article-title":"Idiopathic hyperammonemia: a frequently lethal complication of bone marrow transplantation","volume":"17","author":"Davies","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"2025082801372014000_17.3.e258876.21","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701509822"},{"key":"2025082801372014000_17.3.e258876.22","first-page":"11","article-title":"Hepatic encephalopathy associated with cancer or anticancer therapy","volume":"6","author":"Willson","year":"2013","journal-title":"Gastrointest Cancer Res"},{"key":"2025082801372014000_17.3.e258876.23","doi-asserted-by":"publisher","DOI":"10.1016\/0270-9139(94)90240-2"},{"key":"2025082801372014000_17.3.e258876.24","article-title":"Branched-chain amino acids for people with hepatic encephalopathy","volume":"5","author":"Gluud","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082801372014000_17.3.e258876.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(05)80106-0"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-258876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:37:30Z","timestamp":1756370250000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-258876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,21]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1136\/bcr-2023-258876"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-258876","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}